Quotables
"Rail travel at high speeds is not possible because passengers, unable to breathe, would die of asphyxia."
Dionysius Lardner, Professor of Natural Philosophy and Astronomy at University College, London ; 1830
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120045511 | THERMOSENSITIVE HEPATITIS B VACCINE A thermosensitive hepatitis B vaccine is provided. The thermosensitive hepatitis B vaccine includes an aqueous phase solution comprising a biodegradable thermosensitive hydrogel copolymer; a surface antigen of hepatitis B virus (HBsAg); and a bioactive substance. The th... | 02/23/2012 |
| 20120045430 | DENDRIMER-LIKE MODULAR DELIVERY VECTOR Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, ca... | 02/23/2012 |
| 20120039842 | COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include ... | 02/16/2012 |
| 20120020998 | PLASMACYTOID DENDRITIC CELL LINE USED IN ACTIVE OR ADOPTIVE CELL THERAPY The present invention relates to a method for inducing and amplifying specific effectors, which comprises obtaining pulsed plasmacytoid dendritic cells (pDC) by incubation of a pDC line with at least one antigen, the pulsed pDC being subsequently irradiated and brought ... | 01/26/2012 |
| 20120014989 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related dise... | 01/19/2012 |
| 20120003277 | NANOEMULSION VACCINES The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the sam... | 01/05/2012 |
| 20110293658 | USE OF INKT OR TLR AGONISTS FOR PROTECTING AGAINST OR TREATING A DISEASE SUCH AS ACUTE INFECTION OR CANCER A method of protecting a mammalian subject against, or treating, a disease, wherein the mammalian subject has elevated numbers and/or activities of MDSC comprising administering to the subject a pharmaceutically acceptable amount of an iNKT agonist, such as alpha galact... | 12/01/2011 |
| 20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically accepta... | 12/01/2011 |
| 20110236422 | VARIANTS OF HEPATITIS B VIRUS WITH RESISTANCE TO ANTI-VIRAL NUCLEOSIDE AGENTS AND APPLICATIONS THEREOF The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting co... | 09/29/2011 |
| 20110223197 | Mucosal and Systemic Immunization with Alphavirus Replicon Particles Mucosal and systemic administration of compositions comprising alphavirus replicon particles to induce immune responses in a subject is described.... | 09/15/2011 |
| 20110182939 | Vaccine Adjuvants The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-recept... | 07/28/2011 |
| 20110165194 | HBV Vaccine and a Process of Preparing the Same The present invention relates to an HBV vaccine comprising an entire hepatitis B surface antigen of L protein, M protein and S protein, in which the produced antigens form virus-like particles, and a multi-antigen vaccine further comprising an HBV core antigen in additi... | 07/07/2011 |
| 20110129489 | METHODS FOR GENERATING AN IMMUNE RESPONSE USING DNA AND A VIRAL VECTOR The present invention relates to the generation of an immune response against a target antigen using a DNA and viral vector in a specific administration pattern.... | 06/02/2011 |
| 20110110979 | METHOD AND VACCINE FOR OPTIMIZING THE SPECIFIC IMMUNE RESPONSES The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus (HPV) infection or an associated disease or lesion in a subject.... | 05/12/2011 |
| 20110097362 | Transmucosal Administration of Aggregated Antigens The present invention relates to modulation of the immune response in a mammal. In particular, the invention relates to methods of inducing oral tolerance and systemic immunity in a mammal. The invention sets forth methods and compositions useful in inducing oral tolera... | 04/28/2011 |
| 20110091501 | Recombinant Rhinovirus Vectors The invention provides rhinovirus vectors, which can be used in the delivery of immunogens, such as influenza virus immunogens, and corresponding compositions and methods.... | 04/21/2011 |
| 20110059132 | COMPOSITION FOR THERAPY AND/OR FOR PROPHYLAXIS OF HBV-INFECTIONS AND HBV-MEDIATED DISEASES The present invention relates to a composition, comprising: i) an HBcAg1-x, wherein x is a whole number from the range from 100 to 160, a fragment of this antigen, a variant of this antigen or of the fragment of this antigen or at least two thereof, ii) an ad... | 03/10/2011 |
| 20110052496 | HOLLOW NANOPARTICLES AND USES THEREOF Aspects of the invention provide hollow nanoparticles and uses thereof. In particular, the invention provides membrane-enclosed vesicles comprising a truncated form of an HBsAg S protein lacking one or two of its amino-terminal transmembrane domains.... | 03/03/2011 |
| 20110027318 | NUCLEOTIDE VECTOR, COMPOSITION CONTAINING SUCH VECTOR, AND VACCINE FOR IMMUNIZATION AGAINST HEPATITIS Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis. Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gen... | 02/03/2011 |
| 20110020397 | HYDROPHOBIC MODIFIED PRES-DERIVED PEPTIDES OF HEPATITIS B VIRUS (HBV) AND THEIR USE AS HBV AND HDV ENTRY INHIBITORS The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are derived from a HBV preS consensus sequence and are N-terminal preferably acylated and optional C-terminal modified. These hydrophobic modified preS-derived p... | 01/27/2011 |
| 20110014229 | Chimeric flavivirus vectors The invention provides chimeric flavivirus vectors including foreign peptides inserted into the envelope proteins of the vectors and methods of using these vectors.... | 01/20/2011 |
| 20110002961 | Interleukin 12 paracrine gene delivery enhanced CTL immunotherapy A method of treating a patient with a disease wherein the patient contains diseased cells which cells contain antigens for identification and which cells are capable of presenting at least part of said antigen on their surface by an HLA class I (or equivalent) molecule,... | 01/06/2011 |
| 20100316669 | VACCINE FORMULATION POTENTIATED BY THE COMBINATION OF DNA AND AN ANTIGEN Formulation of vaccine antigens, containing as main components: a-) one or several DNA expressing one or several proteins in the immunized individuals and b-) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of componen... | 12/16/2010 |
| 20100313298 | EXPRESSION CASSETTE, T-DNA MOLECULE, PLANT EXPRESSION VECTOR, TRANSGENIC PLANT CELL AS WELL AS THEIR USE IN THE MANUFACTURING OF A VACCINE The described binary vector with containing the expression cassette of the S-HBsAg protein under the control of the constitutive 35S promoter as well as the method of transforming lettuce using a strain of Agrobacterium tumefaciens containing the vector, facilita... | 12/09/2010 |
| 20100297170 | VACCINES The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinos... | 11/25/2010 |
| 20100285064 | ADJUVANT COMPOSITION FOR VACCINE The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.... | 11/11/2010 |
| 20100285060 | ALPHA THYMOSIN PEPTIDES AS VACCINE ENHANCERS The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclos... | 11/11/2010 |
| 20100272805 | HYDROGELS FOR COMBINATORIAL DELIVERY OF IMMUNE-MODULATING BIOMOLECULES One embodiment of the current disclosure relates to an immune-modulating composition comprising a hydrogel-forming polymer, an immune-modulating biomolecule operable to recruit or retain an immune cell, and an antigen-related biomolecule. Another embodiment of the curre... | 10/28/2010 |
| 20100266534 | Human Lymphocyte Vaccine Adjuvant The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent... | 10/21/2010 |
| 20100247573 | Stabilization of Vaccines by Lyophilization This invention provides pharmaceutical compositions, such as vaccines, and methods of making and using such compositions.... | 09/30/2010 |
| 20100239608 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS The present invention relates to a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region and is optimised for the translation. The pharmaceutical composition according to the invention is particularly suitabl... | 09/23/2010 |
| 20100172937 | ENVELOPED VIRUS NEUTRALIZING COMPOUNDS Methods for reducing infectivity by providing an enveloped virus neutralizing compound (EVNC) are provided. Methods of preparing a vaccine, vaccine formulations, and methods of immunizing a subject a further provided. Methods of disinfecting a surface are still further ... | 07/08/2010 |
| 20100151031 | DISCRETE SIZE AND SHAPE SPECIFIC ORGANIC NANOPARTICLES DESIGNED TO ELICIT AN IMMUNE RESPONSE The presently disclosed invention is broadly directed to therapeutic micro- and/or nanoparticles designed to target an immune cell with an active agent. More particularly, the particles have a predetermined geometry and a broadest dimension of less than about 10 μm. Th... | 06/17/2010 |
| 20100136043 | COMPOSITION COMPRISING IMMUNOGENIC MICROPARTICLES The invention provides an immunogenic composition comprising at least one antigen in association with micropar-tides, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting ... | 06/03/2010 |
| 20100112078 | POLYMER PARTICLES BASED VACCINE The present invention provides a vaccine composition comprising an effective amount of antigen or a nucleic acid encoding antigen, encapsulated in polymeric particles, wherein said polymeric particles comprises nanoparticles, microparticles or combinations thereof, wher... | 05/06/2010 |
| 20100068228 | Inducing Cellular Immune Responses to Hepatitis B Virus Using Peptide and Nucleic Acid Compositions This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the ... | 03/18/2010 |
| 20100055129 | MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF INDENTIFIYING AGENTS THAT MODULATE MYC Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune respons... | 03/04/2010 |
| 20100047281 | VARIANTS OF HEPATITIS B VIRUS WITH RESISTANCE TO ANTI-VIRAL NUCLEOSIDE AGENTS AND APPLICATIONS THEREOF The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting co... | 02/25/2010 |
| 20100040576 | Modified Oligonucleotides For The Treatment Of Hepatitis C Infection The invention relates to compositions and methods related to the treatment of viral infection. In some embodiments, the invention relates to the treatment of hepatitis C viral infection. In further embodiments, the invention relates to methods of administering oligonucl... | 02/18/2010 |
| 20100028433 | IMMUNOGENIC COMPOSITIONS COMPRISING NANOEMULSION AND HEPATITIS B VIRUS IMMUNOGEN AND METHODS OF USING THE SAME The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides immunogenic compositions and methods of using the same to induce immune responses (e.g., immunity (e.g., protective immunity)) a... | 02/04/2010 |
